Renu Dinkar
Pharmaceutical Science
October 2025
Breast cancer is a heterogeneous tumor with limited treatment options. To address this challenge, we developed a targeted delivery system using solid lipid nanoparticles (SLNs) loaded with β-caryophyllene oxide (BCPO), a natural anticancer compound. The SLNs were optimized using factorial design and conjugated with folic acid for active targeting. The developed formulation showed a particle size of 178 nm and sustained drug release, with only 9% of the drug released over 24 hours. In vitro cytotoxicity studies demonstrated enhanced anticancer activity against breast cancer cell lines (MDA-MB-468 and MCF-7), while showing reduced toxicity towards healthy cells. Acute toxicity studies confirmed the safety of the formulation. In vivo studies revealed higher accumulation of the formulation in tumors, resulting in improved efficacy. The formulation arrested tumor growth with a T/C ratio of 0.37, compared to 0.63 for the standard anticancer agent Adriamycin. Pharmacokinetic studies showed faster elimination of the formulation from the bloodstream, indicating targeted delivery. Our study demonstrates the potential of targeted SLNs loaded with BCPO for breast cancer treatment. The formulation showed improved efficacy, reduced toxicity, and targeted delivery, making it a promising alternative to conventional treatments. The use of natural excipients and a scalable manufacturing process further enhances its potential for clinical translation.
45- 79
© Airo Journals 2021
